Get started
Author

Jodie Crawford

Observed names: Crawford, Jodie, J Crawford, J. Crawford, JODIE V CRAWFORD
Observed institutions: GlaxoSmithKline (United Kingdom), Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, University of Manchester, GlaxoSmithKline (Germany), GlaxoSmithKline Research & Development Limited (United Kingdom)
ORCID: 0000-0003-0150-0333
Observed ORCID: 0000-0003-0150-0333
OpenAlex ID: A5055396759
Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice
2016 · Jørgen Vestbo, David Leather, et al. · New England Journal of Medicine · 203
Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial
2013 · William W Busse, Paul M O'Byrne, et al. · Thorax · 75
Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability
2018 · Ashley Woodcock, Isabelle Boucot, et al. · European Respiratory Journal · 42
PDF
Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: A randomized trial
2014 · Jiangtao Lin, Jian Kang, et al. · Respiratory Medicine · 21
Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study
2021 · Yoichi Nakamura, Soichiro Hozawa, et al. · Current Medical Research and Opinion · 14
Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist
2016 · Jiangtao Lin, Huaping Tang, et al. · Allergy and Asthma Proceedings · 12
Is Asthma Clinical Remission Achievable by Inhaled Therapy? A Post-Hoc Analysis of Single Inhaler Triple Therapy with FF/UMEC/VI in the CAPTAIN Trial
2024 · Njira Lugogo, John Oppenheimer, et al. · Journal of Allergy and Clinical Immunology · 10
Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN
2025 · John Oppenheimer, Ian D. Pavord, et al. · Advances in Therapy · 9
PDF
Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups
2019 · Nawar Diar Bakerly, Ashley Woodcock, et al. · Respiratory Medicine · 6
PDF
Defining disease stability in chronic obstructive pulmonary disease: evidence from phase 3 clinical trials
2026 · Dave Singh, Rianne Stacey, et al. · American Journal of Respiratory and Critical Care Medicine · 5
The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease
2021 · Nawar Diar Bakerly, Dominy Browning, et al. · Therapeutic Advances in Respiratory Disease · 5
Assessment of Disease Stability in Patients With COPD Receiving Single-Inhaler Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI: Post Hoc Analysis of the IMPACT Trial
2025 · M.K. Han, D. Singh, et al. · American Journal of Respiratory and Critical Care Medicine · 4
A Pragmatic RCT of FF/UMEC/VI in Patients with Uncontrolled Asthma: PERFORM Protocol
2026 · Stephen G. Noorduyn, Nicola Brown, et al. · Pulmonary Therapy · 3
PDF
A multicenter randomized, double‐blind, placebo‐controlled, parallel‐group study to evaluate the effects of a 1‐year regimen of orally inhaled fluticasone furoate 50 µg once daily on growth velocity in prepubertal, pediatric participants with well‐controlled asthma
2023 · Philippe Bareille, Varsha Imber, et al. · Pediatric Pulmonology · 3
PDF
Misconceptions of Traits to Predict Response to Inhaled Corticosteroid and Bronchodilator Therapies in Asthma: A Narrative Review
2025 · Guy Brusselle, Jodie Crawford, et al. · Pulmonary Therapy · 2
PDF
Effect of Chronic Mucus Hypersecretion on Patients With COPD Achieving and Maintaining Disease Stability With Fluticasone Furoate/Umeclidinium/Vilanterol Versus Budesonide/Formoterol: A FULFIL Post Hoc Analysis
2025 · F. Wang, A. Majumdar, et al. · American Journal of Respiratory and Critical Care Medicine · 2
Influence of Different Thresholds for Asthma Control on Clinical Remission Composite Outcome in Patients Uncontrolled on ICS/LABA: A Post-hoc Analysis of Single Inhaler Triple Therapy With FF/UMEC/VI in the CAPTAIN Trial
2024 · J. Oppenheimer, I. Pavord, et al. · American Journal of Respiratory and Critical Care Medicine · 2
Clinical Remission with FF/UMEC/VI Versus ICS/LABA in Uncontrolled Asthma: The PERFORM Pragmatic Randomized Controlled Trial
2026 · Stephen G. Noorduyn, John J. Oppenheimer, et al. · Advances in Therapy · 1
PDF
Effectiveness of FF/UMEC/VI versus ICS/LABA in Patients with Uncontrolled Asthma Treated in Routine Clinical Practice (PERFORM): A Pragmatic Randomized Controlled Trial
2026 · Erika Penz, Stephen Noorduyn, et al. · Journal of Asthma and Allergy · 1
PDF
Is Clinical Remission, an Ambitious Treatment Goal, Achievable in Patients with Moderate-to-Severe Asthma on Inhaled Therapies: How Ambitious Should We Be?
2026 · Soichiro Hozawa, Risako Ito, et al. · Journal of Clinical Medicine · 1
PDF
Assessment of the components of clinical remission with moderate–severe asthma after 24–52 weeks of treatment: CAPTAIN post hoc analysis
2024 · John Oppenheimer, Njira Lugogo, et al. · European Respiratory Journal · 1
CAPTAIN: Effects of Asthma Onset in Childhood versus Adulthood on Response to Triple Therapy in Patients with Inadequately Controlled Asthma on Inhaled Corticosteroid/Long-Acting β2-Agonist
2021 · W.W. Busse, C.B. Abbott, et al. · American Journal of Respiratory and Critical Care Medicine · 1
LATE-BREAKING ABSTRACT: Effect of fluticasone furoate (FF)/vilanterol (VI) on the rate of COPD exacerbations in everyday clinical practice: Results of the COPD Salford lung study (SLS)
2016 · Jørgen Vestbo, David Leather, et al. · European Respiratory Journal · 1
Late Breaking Abstract - Improvements in asthma symptom control with FF/UMEC/VI versus ICS/LABA usual care: Secondary outcomes from PERFORM, a pragmatic randomised controlled trial
2026 · Alison C Moore, Stephen G Noorduyn, et al. · European Respiratory Journal
Quality of life improvements with FF/UMEC/VI versus ICS/LABA usual care in patients with uncontrolled asthma: Secondary outcomes of PERFORM, a pragmatic randomised controlled trial
2026 · Jodie Crawford, Erika Penz, et al. · European Respiratory Journal
Works count: 45
Citation count: 424
H-index: 8
I10-index: 7
Year
Topic
Type